Payment overview · 2025
General Payments
$1,613.22
85 reported records · 19 companies
Healthcare provider profile · identity verified
Michael J Heise, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MC MURRAY, PA · NPI 1003804162
Verified facts
What the public records show
CMS Open Payments records show Michael J Heise, MD received $1,613.22 in general payments during 2025 across 85 reported records.
Daiichi Sankyo Inc. accounted for 23.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Nuplazid, Ozempic, Paxlovid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Synthroid by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nuplazid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $374.83 | 23.2% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $331.28 | 20.5% | 19 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $94.94 | 5.9% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $90.50 | 5.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $83.68 | 5.2% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $81.45 | 5.0% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $78.86 | 4.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.26 | 4.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $73.10 | 4.5% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $62.32 | 3.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.98 | 3.2% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $47.43 | 2.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $38.85 | 2.4% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $28.16 | 1.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $27.31 | 1.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.99 | 1.5% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $18.06 | 1.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.89 | 1.1% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.33 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,613.22 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $374.83 | 17 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $147.80 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $133.43 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $76.42 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.42 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.28 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $73.26 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.26 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $73.10 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $62.32 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $49.66 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $49.66 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $47.43 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.92 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $38.85 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $37.14 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.05 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.02 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $27.31 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 327 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
97 | 22 |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
327 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
327 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 628 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 455 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 431 | 106 |
| Pantoprazole Sodium | Pantoprazole Sodium | 379 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 370 | 70 |
| Lisinopril | Lisinopril | 348 | 76 |
| Eliquis | Apixaban | 327 | 48 |
| Furosemide | Furosemide | 303 | 59 |
| Omeprazole | Omeprazole | 271 | 58 |
| Metformin Hcl | Metformin Hcl | 269 | 63 |
| Simvastatin | Simvastatin | 245 | 57 |
| Losartan Potassium | Losartan Potassium | 216 | 51 |
| Gabapentin | Gabapentin | 215 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 193 | 31 |
| Donepezil Hcl | Donepezil Hcl | 170 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 167 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 165 | 27 |
| Lorazepam | Lorazepam | 161 | 25 |
| Sertraline Hcl | Sertraline Hcl | 154 | 33 |
| Trazodone Hcl | Trazodone Hcl | 152 | 32 |
| Carvedilol | Carvedilol | 148 | 33 |
| Alprazolam | Alprazolam | 143 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 143 | 38 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 137 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 135 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 35 |
| Prednisone | Prednisone | 133 | 54 |
| Tramadol Hcl | Tramadol Hcl | 130 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 126 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 122 | 20 |
| Montelukast Sodium | Montelukast Sodium | 121 | 24 |
| Finasteride | Finasteride | 118 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 106 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 25 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | 13 |
| Xarelto | Rivaroxaban | 102 | 12 |
| Baclofen | Baclofen | 98 | 16 |
| Synthroid | Levothyroxine Sodium | 97 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 96 | 21 |
| Glimepiride | Glimepiride | 93 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 91 | 17 |
| Famotidine | Famotidine | 87 | 22 |
| Levetiracetam | Levetiracetam | 87 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 86 | 16 |
| Atenolol | Atenolol | 84 | 20 |
| Jardiance | Empagliflozin | 81 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 15 |
| Potassium Chloride | Potassium Chloride | 77 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | suppressed |
| Ozempic | Semaglutide | 68 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 15 |
| Allopurinol | Allopurinol | 67 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 66 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 65 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 15 |
| Warfarin Sodium | Warfarin Sodium | 63 | suppressed |
| Mirtazapine | Mirtazapine | 60 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 39 |
| Spironolactone | Spironolactone | 57 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 56 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 12 |
| Memantine Hcl | Memantine Hcl | 51 | 11 |
| Clonazepam | Clonazepam | 48 | suppressed |
| Bupropion Xl | Bupropion Hcl | 46 | suppressed |
| Nystatin | Nystatin | 46 | 16 |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Azithromycin | Azithromycin | 44 | 33 |
| Januvia | Sitagliptin Phosphate | 44 | 11 |
| Cefuroxime | Cefuroxime Axetil | 41 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Sulfasalazine Dr | Sulfasalazine | 40 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 15 |
| Ibuprofen | Ibuprofen | 36 | 15 |
| Labetalol Hcl | Labetalol Hcl | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 35 | suppressed |
| Meloxicam | Meloxicam | 35 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 15 |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 31 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 11 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Rivastigmine | Rivastigmine | 23 | suppressed |
| Etodolac | Etodolac | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Lacosamide | Lacosamide | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Pen Needles | Pen Needle, Diabetic | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Trospium Chloride | Trospium Chloride | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 14 | suppressed |
| Apidra Solostar | Insulin Glulisine | 13 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 12 |
| Haloperidol | Haloperidol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,613.22 · 85 records | Daiichi Sankyo Inc. | ABRYSVO, AREXVY, AUSTEDO XR, CAPLYTA, COMIRNATY, CONTRAVE, ELIQUIS, FREESTYLE LIBRE 3, INGREZZA, INJECTAFER, KISUNLA, MOUNJARO, NUPLAZID, NURTEC ODT, ONZETRA XSAIL, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, Symbravo, TONMYA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error